In addition, it has been suggested that elevated plasma BCAA in individuals with T2DM originates from a blunted inhibitory effect of insulin on proteolysis [16–18] and/or a compromised mitochondrial BCAA metabolism [19–22]. This evidence concerns the gene INS and type 2 diabetes mellitus.